Shots:

• Bioeq to receive up front- regulatory and launch milestones with equal profit sharing. Coherus to get exclusive rights to commercialize biosimilar candidate referencing Genentech’s Lucentis with its anticipated launch in 2021 in the US
• Bioeq will be responsible for product delivery to the Coherus and will submit BLA to the US FDA in Q4’19
• The biosimilar of Lucentis- being evaluated in P-III study for wet age-related macular degeneration demonstrated bio similarity with the reference product. Bioeq will partner with other companies for its biosimilar ranibizumab outside the US by 2020

Source1- Source 2 to­ read full press release/ article | Ref: Coherus- PRNewswire | Image: Coherus